Chem. J. Chinese Universities ›› 2025, Vol. 46 ›› Issue (10): 20250123.doi: 10.7503/cjcu20250123

• Organic Chemistry • Previous Articles     Next Articles

Design, Synthesis and Biological Evaluation of ERK Inhibitors with Isoindolin-1-one Structure

ZHANG Lingzhi1(), JU Qiurong2, GUAN Zhe3, ZHU Qihua2, ZHANG Tingting1, YANG Shiqin1, XU Yungen2   

  1. 1.College of Biopharmacy,Suzhou Chien?Shiung Institute of Technology,Suzhou 215411,China
    2.Department of Medical Chemistry,China Pharmaceutical University,Nanjing 210009,China
    3.Innovent Biologics(Suzhou) Co. Ltd. ,Suzhou 215123,China
  • Received:2025-04-25 Online:2025-10-10 Published:2025-06-25
  • Contact: ZHANG Lingzhi E-mail:zhanglingzhicpu@163.com
  • Supported by:
    the Natural Science Foundation of the Jiangsu Higher Education Institutions of China(23KJB350008);the Taicang Research Foundation for Basic Research Plan General Project, China(TC2024JC21)

Abstract:

Using the ERK inhibitor EK-I-22 and MK-8353 as the lead compounds, 14 compounds were designed and synthesized by pharmacophore fusion strategy. Preliminary pharmacological activity assessments revealed that compounds 19a(IC50=16 nmol/L), 19b(IC50=15 nmol/L), 19e(IC50=20 nmol/L), 27a(IC50=19 nmol/L) and 27b(IC50=56 nmol/L) exhibited significant inhibitory activity against ERK2 kinase. Notably, compound 27b demonstrated moderate inhibitory effects against four human tumor cell lines(Colo-205, A375, A2058 and HT-29).

Key words: MAPK pathway, ERK inhibitors, Synthesis, Antitumor activity

CLC Number: 

TrendMD: